Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Voorraadrapport

Marktkapitalisatie: US$2.8b

Protagonist Therapeutics Beheer

Beheer criteriumcontroles 4/4

Protagonist Therapeutics' CEO is Dinesh Patel, appointed in Dec 2008, has a tenure of 15.92 years. total yearly compensation is $7.07M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth $19.60M. The average tenure of the management team and the board of directors is 3.8 years and 9.8 years respectively.

Belangrijke informatie

Dinesh Patel

Algemeen directeur

US$7.1m

Totale compensatie

Percentage CEO-salaris9.3%
Dienstverband CEO15.9yrs
Eigendom CEO0.7%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur9.8yrs

Recente managementupdates

Recent updates

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06
An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21
This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

Protagonist EPS beats by $0.03, beats on revenue

May 04

Analyse CEO-vergoeding

Hoe is Dinesh Patel's beloning veranderd ten opzichte van Protagonist Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Sep 30 2019n/an/a

-US$74m

Jun 30 2019n/an/a

-US$66m

Mar 31 2019n/an/a

-US$45m

Dec 31 2018US$4mUS$520k

-US$39m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$24m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$790kUS$475k

-US$37m

Compensatie versus markt: Dinesh's total compensation ($USD7.07M) is about average for companies of similar size in the US market ($USD6.66M).

Compensatie versus inkomsten: Dinesh's compensation has been consistent with company performance over the past year.

CEO

Dinesh Patel (67 yo)

15.9yrs

Tenure

US$7,067,572

Compensatie

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He served as Interim Chief Financ...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dinesh Patel
CEO, President15.9yrsUS$7.07m0.71%
$ 19.6m
Asif Ali
Executive VP & Chief Financial Officer2.6yrsUS$1.40m0%
$ 0
Suneel Gupta
Chief Development Officer5.8yrsUS$2.22m0.25%
$ 6.9m
Mark Smythe
Founder & VP Technology3.8yrsgeen gegevensgeen gegevens
Mohammad Masjedizadeh
Executive VP & Chief Technical Officer3.8yrsgeen gegevensgeen gegevens
Matthew Gosling
Executive VP & General Counsel4.2yrsgeen gegevensgeen gegevens
Carena Spivey
Head of HR & Senior VP of Human Resources3.8yrsgeen gegevensgeen gegevens
Ashok Bhandari
Executive VP & Chief Drug Discovery and Preclinical Development Officer3.8yrsgeen gegevensgeen gegevens
Carter King
Executive Vice President of Business Development3.6yrsgeen gegevensgeen gegevens
Abha Bommireddi
Executive Vice President of Portfolio & Program Management3.8yrsgeen gegevensgeen gegevens
Arturo Molina
Chief Medical Officer2yrsgeen gegevens0.0069%
$ 190.6k
Samuel Saks
Clinical Development Advisor3.8yrsgeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: PTGX's management team is considered experienced (3.8 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Dinesh Patel
CEO, President15.9yrsUS$7.07m0.71%
$ 19.6m
Harlan Weisman
Clinical Advisor9.8yrsgeen gegevensgeen gegevens
Lewis Williams
Independent Director7.4yrsUS$351.52k0%
$ 0
Chaitan Khosla
Chairman of Scientific Advisory Board9.8yrsUS$188.07kgeen gegevens
Harold Selick
Independent Chairman15.8yrsUS$395.27k0.048%
$ 1.3m
William Waddill
Independent Director8.3yrsUS$364.02k0.020%
$ 561.1k
Charles Craik
Scientific Advisorno datageen gegevensgeen gegevens
Mark Gallop
Scientific Advisorno datageen gegevensgeen gegevens
Wayne Lencer
Clinical Advisorno datageen gegevensgeen gegevens
Aida Habtezion
Clinical Advisorno datageen gegevensgeen gegevens
Ellen Scherl
Clinical Advisorno datageen gegevensgeen gegevens
Bryan Giraudo
Independent Director6.5yrsUS$356.52k0.031%
$ 841.7k

9.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: PTGX's board of directors are considered experienced (9.8 years average tenure).